LONG-TERM EFFICACY AND SAFETY OF SIRUKUMAB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE ANTI-TUMOR NECROSIS FACTOR THERAPY: RESULTS OF THE RANDOMIZED, PHASE 3 SIRROUND-T STUDY

被引：0
|
作者：
Tanaka, Y. [1 ]
Aletaha, D. [2 ]
Agarwal, P. [3 ]
Kurrasch, R. [4 ]
Tak, P. P. [5 ]
Popik, S. [3 ]
机构：
[1] Univ Occupat & Environm Hlth, Dept Internal Med, Kitakyushu, Fukuoka, Japan
[2] Med Univ Vienna, Div Rheumatol, Vienna, Austria
[3] Janssen Res & Dev LLC, Spring House, PA USA
[4] GlaxoSmithKline, Collegeville, PA USA
[5] GlaxoSmithKline, Stevenage, Herts, England
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2017年 / 76卷
关键词：
D O I：
10.1136/annrheumdis-2017-eular.6486
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
FRI0214
引用
收藏
页码：563 / 564
页数：2
相关论文
共 50 条
  • [21] Efficacy and Safety of Sirukumab, an Anti-IL-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis Despite Anti-TNF Therapy: Results from a Randomized, Double-Blind, Placebo-Controlled, Global, Phase 3 Study
    Aletaha, Daniel
    Bingham, Clifton, III
    Tanaka, Yoshiya
    Agarwal, Prasheen
    Kurrasch, Regina
    Tak, Paul-Peter
    Popik, Sharon
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [22] Long-term Safety and Efficacy of Sarilumab over 5 Years in Patients with Rheumatoid Arthritis Refractory to Tumor Necrosis Factor Inhibitors
    Fleischmann, Roy
    Maslova, Karina
    Leher, Henry
    Praestgaard, Amy
    Burmester, Gerd
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [23] LONG-TERM SAFETY AND EFFICACY OF SARILUMAB OVER 5 YEARS IN PATIENTS WITH RHEUMATOID ARTHRITIS REFRACTORY TO TUMOR NECROSIS FACTOR INHIBITORS
    Fleischmann, R.
    Genovese, M. C.
    Maslova, K.
    Leher, H.
    Praestgaard, A.
    Burmester, G. R.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 620 - 621
  • [24] A long-term study to evaluate the safety and efficacy of meloxicam therapy in patients with rheumatoid arthritis
    Huskisson, EC
    Ghozlan, R
    Kurthen, R
    Degner, FL
    Bluhmki, E
    BRITISH JOURNAL OF RHEUMATOLOGY, 1996, 35 : 29 - 34
  • [25] Long-term effects of anti-tumour necrosis factor therapy on weight in patients with rheumatoid arthritis
    Brown, Rachel A.
    Spina, Domenico
    Butt, Sayqa
    Summers, Gregory D.
    CLINICAL RHEUMATOLOGY, 2012, 31 (03) : 455 - 461
  • [26] Long-term effects of anti-tumour necrosis factor therapy on weight in patients with rheumatoid arthritis
    Rachel A. Brown
    Domenico Spina
    Sayqa Butt
    Gregory D. Summers
    Clinical Rheumatology, 2012, 31 : 455 - 461
  • [27] Safety of anti-tumor necrosis factor-α therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection
    Ferri, Clodoveo
    Ferraccioli, Gianfranco
    Ferrari, Daniela
    Galeazzi, Mauro
    Lapadula, Giovanni
    Montecucco, Carlomaurizio
    Triolo, Giovanni
    Valentini, Gabriele
    Valesini, Guido
    JOURNAL OF RHEUMATOLOGY, 2008, 35 (10) : 1944 - 1949
  • [28] Integrated Phase 3 Safety Results of Sirukumab, an Anti-IL-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis
    Aletaha, Daniel
    Thorne, Carter
    Schiff, Michael
    Harigai, Masayoshi
    Agarwal, Prasheen
    Rao, Ravi
    Cohen, Christopher
    Cheng, Ben
    Brown, Kurt
    Hsu, Benjamin
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [29] Long-Term Evaluation Of Cardiac Function In Juvenile Idiopathic Arthritis Under Anti-Tumor Necrosis Factor Therapy
    Lianza, Alessandro C.
    Aikawa, Nadia E.
    Moraes, Julio C. B.
    Leal, Gabriela N.
    Morhy, Samira S.
    Bonfa, Eloisa
    Silva, Clovis A.
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S121 - S121
  • [30] EFFICACY AND SAFETY OF SIRUKUMAB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE DISEASE-MODIFYING ANTI-RHEUMATIC DRUG TREATMENT: RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
    Takeuchi, T.
    Thorne, C.
    Karpouzas, G.
    Sheng, S.
    Xu, W.
    Rao, R.
    Fei, K.
    Hsu, B.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 717 - 717
12345